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the probability of postoperative radiation therapy (RT) and postoperative chemoradiotherapy (CRT); survival after resection alone; and survival after resection and adjuvant therapy.
The outcomes assessed in the no initial resection group were: operative mortality for exploration and for subsequent resection; the likelihood of subsequent resection; survival after neoadjuvant therapy and resection; and survival after neoadjuvant therapy alone.
Also assessed were quality of life during postoperative recovery, RT, neoadjuvant or adjuvant CRT, and quality of life after all therapy had been completed.
Study designs and other criteria for inclusion in the review
The design of the primary studies was not reported. Reports published in English from 1990 to 2002 were eligible for inclusion in the review. Articles were selected if they had at least 25 patients in each surgical candidate group and median survival and operative mortality were reported (or calculable) for N2 patients.
Sources searched to identify primary studies
MEDLINE was searched for relevant primary studies using the keywords ("lung resection" and "lung neoplasm") and ("stage III" or "stage IIIa" or "mediastinal adenopathy" or "N2").
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Forty-five primary studies were included in the review.
Methods of combining primary studies
A meta-analysis of the primary estimates was conducted and the weighted mean survival was calculated.
Investigation of differences between primary studies
Results of the review
In the initial resection group, the estimated values were 0.03 (range: 0.01 -0.05) for operative mortality, 0.25 (range: 0.15 -0.35) for the probability of postoperative RT, and 0.5 (range: 0.4 -0.6) for the probability of postoperative CRT. Survival was 1.8 years (range: 1.2 -2.4), both after resection alone and after resection and adjuvant therapy.
In the no initial resection group, the estimated values were 0.005 (range: 0.002 -0.01) for operative mortality for exploration, 0.05 (range: 0.03 -0.07) for operative mortality for subsequent resection, and 0.7 (range: 0.5 -0.9) for the likelihood of subsequent resection. Survival was 2.6 years (range: 2 -3.2) after neoadjuvant therapy and resection, and 1 year (range: 0.8 -1.2) after neoadjuvant therapy alone.
The values of quality of life were 0.75 (range: 0.6 -0.9) for postoperative recovery, 0.7 (range: 0.5 -0.9) for RT, 0.65 (range: 0.5 -0.8) for neoadjuvant or adjuvant CRT, and 0.85 (range: 0.75 -0.95) after all therapy had been completed.
Methods used to derive estimates of effectiveness
Some assumptions were made for periods of decreased quality of life.
Estimates of effectiveness and key assumptions
Periods of decreased quality of life were assumed to be 0.1 years for postoperative patients who were to receive neoadjuvant or adjuvant therapy, 0.2 years for postoperative patients who did not receive neoadjuvant or adjuvant therapy, and 0.2 years for the administration of neoadjuvant or adjuvant therapy. No adjustment was made for quality of life at the end of life.
Measure of benefits used in the economic analysis
The summary benefit measure used was the quality-adjusted life-years (QALYs). These were derived from the decision model. No discounting was applied. The utility values were derived from published studies.
Direct costs
Discounting was not relevant due to the short life expectancy of the patients considered in the study. The unit costs and the quantities of resources used were not reported separately. The health services included in the economic evaluation were RT, CRT, resection, surgical exploration and operative mortality. The cost/resource boundary of the medical centre was used. The resource use data were based on probability values estimated from the review of the literature, which was conducted to derive the effectiveness values. The surgical costs were derived using actual data from a sample of 100 patients who underwent lung resection at the authors' centre from 1998 to 2000. The other costs were estimated from published studies. All the costs were converted into 2002 values using the Consumer Price Index.
